Psyence Biomedical receives Nasdaq notification regarding minimum bid price deficiency
Psyence Biomedical (PBM) received a letter from Nasdaq regarding minimum bid price deficiency, giving them 180 days to regain compliance.
skynesher/E+ via Getty Images Psyence Biomedical (NASDAQ:PBM) said Wednesday it received a letter from Nasdaq for not meeting the minimum bid price of $1.00 per share required for continued listing.Psyence Biomedical (PBM) has 180 calendar days, or until December 24, 2024 to regain compliance with the Minimum Bid Price Rule.Source: Press Release
Disclaimer: The views in this article are from the original author and do not represent the views or position of Hawk Insight. The content of the article is for reference, communication and learning only, and does not constitute investment advice. If it involves copyright issues, please contact us for deletion.